New drug shows promise for tough Crohn's cases
NCT ID NCT05013905
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tested a new drug called tulisokibart (PRA023) in 55 people with moderate-to-severe Crohn's disease who had not responded well to other treatments. The main goals were to check safety and see if the drug could improve gut healing and reduce symptoms. After 12 weeks, some participants could continue treatment for up to 170 weeks to monitor long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prometheus Biosciences Selected Center
Krakow, 31-501, Poland
-
Prometheus Biosciences Selected Center
Warsaw, 00-635, Poland
-
Prometheus Biosciences Selected Center
Warsaw, 52-416, Poland
-
Prometheus Biosciences Selected Site
Los Angeles, California, 90045, United States
-
Prometheus Biosciences Selected Site
Los Angeles, California, 90048, United States
-
Prometheus Biosciences Selected Site
Liberty, Kansas, 64098, United States
-
Prometheus Biosciences Selected Site
Chesterfield, Michigan, 48047, United States
-
Prometheus Biosciences Selected Site
Ypsilanti, Michigan, 48197, United States
-
Prometheus Biosciences Selected Site
St Louis, Missouri, 63141, United States
-
Prometheus Biosciences Selected Site
Lebanon, New Hampshire, 03756, United States
-
Prometheus Biosciences Selected Site
New York, New York, 10065, United States
-
Prometheus Biosciences Selected Site
Garland, Texas, 75044, United States
-
Prometheus Biosciences Selected Site
Lubbock, Texas, 79410, United States
-
Prometheus Biosciences Selected Site
Lubbock, Texas, 79424, United States
-
Prometheus Biosciences Selected Site
San Antonio, Texas, 78229, United States
-
Prometheus Biosciences Selected Site
Southlake, Texas, 78229, United States
-
Prometheus Biosciences Selected Site
Tyler, Texas, 75702, United States
-
Prometheus Biosciences Selected Site
Bellevue, Washington, 98004, United States
-
Prometheus Biosciences Selected Site
Tacoma, Washington, 98405, United States
-
Prometheus Biosciences Selected Site
Bankstown, New South Wales, 2146, Australia
-
Prometheus Biosciences Selected Site
Woolloongabba, Queensland, 4102, Australia
-
Prometheus Biosciences Selected Site
Adelaide, South Australia, 5000, Australia
-
Prometheus Biosciences Selected Site
Leuven, 3000, Belgium
-
Prometheus Biosciences Selected Site
Liège, 4000, Belgium
-
Prometheus Biosciences Selected Site
London, Ontario, N6A 5W9, Canada
-
Prometheus Biosciences Selected Site
Brno, Czechia
-
Prometheus Biosciences Selected Site
Slaný, 274 01, Czechia
-
Prometheus Biosciences Selected Site
Clichy, 92110, France
-
Prometheus Biosciences Selected Site
Nice, 06202, France
-
Prometheus Biosciences Selected Site
Saint-Priest-en-Jarez, 42270, France
-
Prometheus Biosciences Selected Site
Vandœuvre-lès-Nancy, 54511, France
-
Prometheus Biosciences Selected Site
Tbilisi, Georgia
-
Prometheus Biosciences Selected Site
Rzeszów, 35-326, Poland
-
Prometheus Biosciences Selected Site
Sopot, 81-756, Poland
-
Prometheus Biosciences Selected Site
Torun, 87-100, Poland
-
Prometheus Biosciences Selected Site
Warsaw, 03-580, Poland
-
Prometheus Biosciences Selected Site
Wroclaw, 52-416, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?